)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
FibroBiologics (FBLG) investor relations material
FibroBiologics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary31 Oct, 2025
Executive summary
Focused on developing fibroblast-based therapies for chronic diseases, with lead candidates in wound healing, multiple sclerosis, degenerative disc disease, and psoriasis.
Advanced preparations for manufacturing CYWC628, with Phase 1/2 clinical trial for diabetic foot ulcers set to begin in Q1 2026 and complete in Q3 2026, pending resolution of manufacturing process issues.
Preparing to submit IND applications for CYPS317 (psoriasis) and CYMS101 (multiple sclerosis) following completion of preclinical studies.
No revenue generated to date; operations funded through equity, convertible notes, and preferred stock sales.
Net losses continue as R&D and administrative expenses rise, with substantial additional funding required for ongoing operations and clinical development.
Financial highlights
Net loss of $15.4 million for the nine months ended September 30, 2025, compared to $8.1 million for the same period in 2024.
Research and development expenses rose to $6.6 million for the nine months, up from $3.1 million year-over-year, driven by increased contract research, CRO, lab, and personnel costs.
General and administrative expenses increased to $7.4 million from $6.9 million year-over-year, mainly due to higher personnel and professional fees.
Cash and cash equivalents were $4.9 million as of September 30, 2025, down from $14.0 million at December 31, 2024.
Accumulated deficit reached $50.9 million as of September 30, 2025.
Outlook and guidance
Plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia in Q1 2026, with completion expected in Q3 2026, pending manufacturing process resolution.
IND submissions for CYPS317 and CYMS101 anticipated after completion of preclinical studies.
Ongoing need for substantial additional capital; management has implemented cost controls and is prioritizing near-term projects.
No expectation of product revenue in the near term; continued operating losses anticipated.
Manufacturing training runs and sterility confirmation for CYWC628 expected by end of 2025, with cGMP-compliant manufacturing to follow.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next FibroBiologics earnings date
Q4 202530 Mar, 2026
Next FibroBiologics earnings date
Q4 202530 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
FibroBiologics Inc. is a biotechnology company that specializes in regenerative medicine and cell therapy. The company is focused on developing innovative treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds over 150 U.S. and international patents and patents pending, covering various clinical pathways including orthopedics, multiple sclerosis, psoriasis, wound healing, and cancer. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage